Aromatase inhibition 2013: Clinical state of the art and questions that remain to be solved

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages

  Løning, Per Eystein ^a,b   Eikesdal, Hans Petter ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adjuvant therapy; Aromatase inhibitors; Breast cancer; Endocrine therapy; Resistance

Indexed keywords

AMINOGLUTETHIMIDE; AMINOGLUTETHIMIDE PLUS FORMESTANE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; EVEROLIMUS; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; GESTAGEN; GONADORELIN DERIVATIVE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; PYRIDOGLUTETHIMIDE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; AROMATIZATION; ARTHRALGIA; BREAST; BREAST CANCER; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; DRUG BINDING; DRUG DOSE SEQUENCE; DRUG EFFICACY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN SYNTHESIS; HUMAN; METASTASIS; MONOTHERAPY; NONHUMAN; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; PREMENOPAUSE; PROTEIN BINDING; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; THERAPY RESISTANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADJUVANT THERAPY; AROMATASE INHIBITORS; BREAST CANCER; ENDOCRINE THERAPY; RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGENS; FEMALE; HUMANS;

EID: 84882756472     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0099     Document Type: Review

References (181)

1. Agarwal VR, Bulun SE, Leitch M, Rohrich R & Simpson ER 1996 Use of alternative promoters to express the aromatase cytochrome p450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Journal of Clinical Endocrinology and Metabolism 81 3843-3849. (doi:10.1210/jc.81.11.3843)
2. Alexander KP, Newby LK, Hellkamp AS, Harrington RA, Peterson ED, Kopecky S, Langer A, O'Gara P, O'Connor CM, Daly RN et al. 2001 Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. Journal of the American College of Cardiology 38 1-7. (doi:10.1016/S0735-1097(01)01329-8)
3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al. 2004 Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The Women's Health Initiative Randomized Controlled trial. Journal of the American Medical Association 291 1701-1712. (doi:10.1001/jama.291.14.1701)
4. Anker G, Lønning PE, Ueland PM, Refsum H & Lien EA 1995 Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer 60 365-368. (doi:10.1002/ijc.2910600316)
5. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D et al. 2012 Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of Clinical Oncology 30 2718-2724. (doi:10.1200/JCO.2011.39.0708)
6. Baselga J 2011 Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16 12-19. (doi:10.1634/theoncologist.2011-S1-12)
7. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al. 2012 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine 366 520-529. (doi:10.1056/NEJMoa1109653)
8. Beatson GT 1896 On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet 2 104-107. (doi:10.1016/S0140-6736(01)72307-0)
9. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R et al. 2012 Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. Journal of Clinical Oncology 30 709-717. (doi:10.1200/JCO.2010.33.7899)
10. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C et al. 2006 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Annals of Oncology 17 VII10-VII14. (doi:10.1093/annonc/mdl941)
11. Boccardo F, Guglielmini P, Bordonaro R, Fini A, Massidda B, Porpiglia M, Roagna R, Serra P, Orzalesi L, Ucci G et al. 2013 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial. European Journal of Cancer 49 1546-1554. (doi:10.1016/j.ejca.2012.12.025)
12. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K et al. 2006 Homocysteine lowering and cardiovascular events after acute myocardial infarction. New England Journal of Medicine 354 1578-1588. (doi:10.1056/NEJMoa055227)
13. Brodie AMH, Schwarzel WC, Shaikh AA & Brodie HJ 1977 The effect of an aromatase inhibitor, 4-hydroxy-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100 1684-1695. (doi:10.1210/endo-100-6-1684)
14. Brodie AMH, Garrett WM, Hendrickson JR, Tsai-Morris CH & Williams JG 1983 Aromatase inhibitors, their pharmacology and application. Journal of Steroid Biochemistry 19 53-58. (doi:10.1016/S0022-4731(83)80006-5)
15. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H & Shozu M 2003 The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. Journal of Steroid Biochemistry and Molecular Biology 86 219-224. (doi:10.1016/S0960-0760(03)00359-5)
16. Cabodi S, Moro L, Baj G, Smeriglio M, Di Stefano P, Gippone S, Surico N, Silengo L, Turco E, Tarone G et al. 2004 p130Cas interacts with estrogen receptor a and modulates non-genomic estrogen signaling in breast cancer cells. Journal of Cell Science 117 1603-1611. (doi:10.1242/jcs.01025)
17. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S & Nakshatri H 2001 Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor a - a new model for anti-estrogen resistance. Journal of Biological Chemistry 276 9817-9824. (doi:10.1074/jbc.M010840200)
18. Cash R, Brough AJ, Cohen MNP & Satoh PS 1967 Aminoglutethimide (Elipten-Ciba) is an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial. Journal of Clinical Endocrinology and Metabolism 27 1239-1248. (doi:10.1210/jcem-27-9-1239)
19. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P & de Oliveira CT 2006 Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative 'Arimidex' Compared to Tamoxilen (PROAC7) trial. Cancer 106 2095-2103. (doi:10.1002/cncr.21872)
20. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF et al. 2008 Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. Journal of Clinical Oncology 26 1664-1670. (doi:10.1200/JCO.2007.13.5822)
21. Clyne CD, Kovacic A, Speed CJ, Zhou J, Pezzi V & Simpson ER 2004 Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Molecular and Cellular Endocrinology 215 39-44. (doi:10.1016/j.mce.2003. 11.001)
22. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of Clinical Oncology 25 486-492. (doi:10.1200/JCO.2006. 08.8617)
23. Coleman R, Banks L, Girgis S, Kilburn L, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E et al. 2007 Skeletal effects of exemestane on bone-mineral density bone biomarkers and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncology 8 119-127. (doi:10.1016/S1470-2045(07)70003-7)
24. Colleoni M, Giobbie-Hurder A, Regan MM, Thurlimann B, Mouridsen H, Mauriac L, Mauriac L, Forbes JF, Paridaens R, Láng I et al. 2011 Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study. Journal of Clinical Oncology 29 1117-1124. (doi:10.1200/JCO.2010. 31.6455)
25. Coombes RC, Goss P, Dowsett M, Gazet J-C & Brodie A 1984 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 324 1237-1239. (doi:10.1016/S0140-6736(84)92795-8)
26. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 559-570. (doi:10.1016/S0140-6736(07)60200-1)
27. Couzinet B, Meduri G, Lecce M, Young J, Brailly S, Loosfelt H, Milgrom E & Schaison G 2001 The postmenopausal ovary is not a major androgen-producing gland. Journal of Clinical Endocrinology and Metabolism 86 5060-5066. (doi:10.1210/jc.86.10.5060)
28. Davies C, Pan HC, Godwin J, Gray R, Peto R & Collaboratives A 2012 ATLAS - 10 v 5 years of adjuvant tamoxifen (TAM) in ER+ disease; effects on outcome in the first and second decade after diagnosis. Cancer Research 72 (24 suppl) S81-S82.
29. Dawood S, Lei XD, Litton JK, Buchholz TA, Hortobagyi GN & Gonzalez-Angulo AM 2012 Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clinical Breast Cancer 12 364-372. (doi:10.1016/j.clbc.2012.07.013)
30. Dent S, Hopkins S, Di Valentin T, Verreault J, Vandermeer L & Verma S 2007 Adjuvant aromatase inhibitors in early breast cancer - toxicity and adherence. Important observations in clinical practice. Breast Cancer Research and Treatment 106 (S1) S111.
31. Diorio C, Lemieux J, Provencher L, Hogue JC & Vachon E 2012 Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels. Breast Cancer Research and Treatment 136 573-579. (doi:10.1007/s10549-012-2278-z)
32. Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP & Dowsett M 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. Journal of Clinical Oncology 26 1671-1676. (doi:10.1200/JCO.2007.13.9279)
33. Dixon JM, Renshaw L, Macaskill EJ, Young O, Murray J, Cameron D, Kerr GR, Evans DB & Miller WR 2009 Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Research and Treatment 113 145-151. (doi:10.1007/s10549-008-9915-6)
34. Dizdar O, Ozcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y & Altundag K 2009 Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. Journal of Clinical Oncology 27 4955-4960. (doi:10.1200/JCO.2008.20.5435)
35. Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL & Coombes RC 1987 Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Research 47 1957-1961. (Pubitemid 17056706)
36. Dowsett M, Cantwell B, Lal A, Jeffcoate SL & Harris AL 1988 Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hor-mone- releasing hormone agonist goserelin. Journal of Clinical Endocrinology and Metabolism 66 672-677. (doi:10.1210/jcem-66-4-672)
37. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P & Smith IE 1995 In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clinical Cancer Research 1 1511-1515. (Pubitemid 26028086)
38. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S & Hills M 2005 Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clinical Cancer Research 11 951S-958S. (Pubitemid 40111111)
39. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M, Walsh G et al. 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 99 167-170. (doi:10.1093/jnci/djk020)
40. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. Journal of Clinical Oncology 26 1059-1065. (doi:10.1200/JCO.2007.12.9437)
41. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M et al. 2010 Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology 28 509-518. (doi:10.1200/JCO.2009.23.1274)
42. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T et al. 2011a Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute 103 1656-1664. (doi:10.1093/jnci/ djr393)
43. Dowsett M, Smith I, Robertson J, Robison L, Pinhel I, Johnson L, Salter J, Dunbier A, Anderson H & Ghazoui Z 2011b Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. Journal of the National Cancer Institute. Monographs 2011 120-123. (doi:10.1093/jncimonographs/lgr034)
44. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F et al. 2012 Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer From the Austrian Breast and Colorectal Cancer Study Group. Journal of Clinical Oncology 30 722-728. (doi:10.1200/JCO.2011.36.8993)
45. Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW & Clack G 2008 Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. Journal of Clinical Oncology 26 1051-1058. (doi:10.1200/JCO. 2007.11.0726)
46. Eiermann W, Paepke S, Appfelstaedt J, Llombart Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA et al. 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology 12 1527-1532. (doi:10.1023/A:1013128213451)
47. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C et al. 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808-3816. (Pubitemid 32880059)
48. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A et al. 2009 Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer a phase 2 randomized study. Journal of the American Medical Association 302 774-780. (doi:10.1001/jama.2009.1204)
49. Engan T, Krane J, Johannessen DC, Lonning PE & Kvinnsland S 1995 Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Research and Treatment 36 287-297. (doi:10.1007/BF00713400)
50. Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thurlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M et al. 2012 Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial. Journal of Clinical Oncology 30 3967-3975. (doi:10.1200/JCO.2011.40.8666)
51. Fedele P, Calvani N, Marino A, Orlando L, Schiavone P, Quaranta A & Cinieri S 2012 Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Critical Reviews in Oncology/Hematology 84 243-251. (doi:10.1016/j.critrevonc.2012.03. 004)
52. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M et al. 2012 Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ERC/HER2K advanced breast cancer (BC). Cancer Research 72 (24 Suppl) S1-S6.
53. Fisher B, Dignam J, Bryant J, Decillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM et al. 1996 Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 88 1529-1542. (doi:10.1093/jnci/88.21.1529)
54. Flageng MH, Moi LL, Dixon JM, Geisler J, Lien EA, Miller WR, Lønning PE & Mellgren G 2009 Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer 101 1253-1260. (doi:10.1038/sj.bjc.6605324)
55. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP & Dowsett M 2012 Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. Journal of Clinical Oncology 30 2977-2980. (doi:10.1200/JCO.2012.42.0273)
56. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS & Baum M 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 45-53. (doi:10.1016/S1470-2045(07)70385-6)
57. Fox EM, Andrade J & Shupnik MA 2009 Novel actions of estrogen to promote proliferation: Integration of cytoplasmic and nuclear pathways. Steroids 74 622-627. (doi:10.1016/j.steroids.2008.10.014)
58. Fracchia AA, Randall HT & Farrow JH 1967 The results of adrenalectomy in advanced breast cancer in 500 consecutive patients. Surgery, Gynecology & Obstetrics 125 747-756.
59. Fracchia AA, Farrow JH, Miller TR, Tollefsen RH, Greenberg EJ & Knapper WH 1971 Hypophysectomy as compared with adrenalectomy in the treatment of advanced carcinoma of the breast. Surgery, Gynecology & Obstetrics 133 241-246.
60. Geisler J & Lønning PE 2005 Aromatase inhibition: translation into a successful therapeutic approach. Clinical Cancer Research 11 2809-2821. (doi:10.1158/1078-0432.CCR-04-2187)
61. Geisler J, Haarstad H, Gundersen S, Raabe N, Kvinnsland S & Lonning PE 1995 Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. Journal of Endocrinology 146 359-363. (doi:10.1677/joe.0.1460359)
62. Geisler J, Johannessen DC, Anker G & Lønning PE 1996a Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated cancer patients: clinical and endocrine effects. European Journal of Cancer 32A 789-792. (doi:10.1016/0959-8049(95)00623-0)
63. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO & Lønning PE 1996b Influence of anastrozole (arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer 74 1286-1291. (doi:10.1038/bjc.1996.531)
64. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE & Dowsett M 1998 In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clinical Cancer Research 4 2089-2093. (Pubitemid 28415652)
65. Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M & Lønning P 2001 Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clinical Cancer Research 7 1230-1236. (Pubitemid 32708674)
66. Geisler J, Haynes B, Anker G, Dowsett M & Lønning PE 2002 Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. Journal of Clinical Oncology 20 751-757. (doi:10.1200/JCO.20.3.751)
67. Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES & Eide GE 2006 Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. European Journal of Cancer 42 2968-2975. (doi:10.1016/j.ejca.2006.07.005)
68. Geisler J, Ekse D, Helle H, Duong N & Lønning P 2008a An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology 109 90-95. (doi:10.1016/j.jsbmb.2007.12.011)
69. Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbø Y, Aas T & Lønning PE 2008b Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clinical Cancer Research 14 6330-6335. (doi:10.1158/1078-0432.CCR-07-5221)
70. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P et al. 2008 Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncology 9 840-849. (doi:10.1016/S1470-2045(08)70204-3)
71. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCICCTG MA.17. Journal of the National Cancer Institute 97 1262-1271. (doi:10.1093/jnci/dji250)
72. Harris AL, Cantwell BMJ & Dowsett M 1988 High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. British Journal of Cancer 58 493-496. (doi:10.1038/bjc.1988.247)
73. Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, Lønning PE & Dowsett M 2010 Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research 16 1790-1801. (doi:10.1158/1078-0432. CCR-09-2481)
74. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C et al. 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396-3403. (doi:10.1200/JCO.2002.10.057)
75. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I et al. 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Journal of Clinical Oncology 22 1605-1613. (doi:10.1200/JCO.2004.02.112)
76. Huggins C & Dao TL-Y 1953 Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. Journal of the American Medical Association 151 1388-1394.
77. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B & Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 280 605-613. (doi:10.1001/jama.280.7.605)
78. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JA, Kubo M, Jenkins GD, Batzler A, Shepherd L et al. 2010 Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. Journal of Clinical Oncology 28 4674-4682. (doi:10.1200/JCO.2010.28.5064)
79. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A & Hall MN 2004 Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature Cell Biology 6 U1122-U1130. (doi:10.1038/ncb1183)
80. Jacobs S, Lønning PE, Haynes B, Griggs L & Dowsett M 1991 Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of Enzyme Inhibition 4 315-325. (doi:10.3109/14756369109030396)
81. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 455-462. (doi:10.1016/S0140-6736(05)67059-6)
82. Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F et al. 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group trial 6a. Journal of the National Cancer Institute 99 1845-1853. (doi:10.1093/jnci/djm246)
83. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST et al. 2010 Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine 16 205-213. (doi:10.1038/nm.2091)
84. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG & Brodie AMH 2005 Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Research 65 5380-5389. (doi:10.1158/0008-5472.CAN-04-4502)
85. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S & Lonning PE 1997 Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clinical Cancer Research 3 1101-1108. (Pubitemid 27319756)
86. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C & Jönsson B 2004 Mortality after osteoporotic fractures. Osteoporosis International 15 38-42. (doi:10.1007/s00198-003-1490-4)
87. Johnston S, Pippen J, Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 27 5538-5546. (doi:10.1200/JCO.2009.23.3734)
88. Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M & Powles TJ 1992 The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. European Journal of Cancer 28A 1712-1716. (doi:10.1016/0959-8049(92)90074-C)
89. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Misso ML, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM et al. 2001 Aromatasedeficient (ArKO) mice accumulate excess adipose tissue. Journal of Steroid Biochemistry and Molecular Biology 79 3-9. (doi:10.1016/S0960-0760(01)00136-4)
90. Jordan NJ, Gee JMW, Barrow D, Wakeling AE & Nicholson RI 2004 Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 87 167-180. (doi:10.1023/B:BREA.0000041623.21338.47)
91. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A & Ogelsby AK 2002 International variation in hip fracture probabilities: implications for risk assessment. Journal of Bone and Mineral Research 17 1237-1244. (doi:10.1359/jbmr.2002.17.7.1237)
92. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A et al. 2009 Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the Randomized Phase III TAnDEM Study. Journal of Clinical Oncology 27 5529-5537. (doi:10.1200/JCO.2008.20.6847)
93. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G & Zuna I 2007 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. Journal of Clinical Oncology 25 2664-2670. (doi:10.1200/JCO.2006.08.8054)
94. Kendall A, Dowsett M, Folkerd E & Smith I 2006 Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of Oncology 17 584-587. (doi:10.1093/annonc/mdj127)
95. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE, Jr, Falk RT, Miller R et al. 2003 Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute 95 1218-1226. (doi:10.1093/jnci/djg022)
96. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144 1032-1044. (doi:10.1210/en.2002-220620)
97. Kofman S, Nagamani D, Buenger RF & Taylor SG 1958 The use of prednisolone in the treatment of disseminated breast carcinoma. Cancer 11 226-232. (doi:10.1002/1097-0142(195801/02)11:1〈226::AID- CNCR2820110135〉3.0.CO;2-S)
98. Kwan ML, Chen WY, Kroenke CH, Weltzien EK, Beasley JM, Nechuta SJ, Poole EM, Lu W, Holmes MD, Quesenberry CP, Jr et al. 2012 Prediagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment 132 729-739. (doi:10.1007/s10549-011-1914- 3)
99. van Landeghem AJJ, Poortman J, Nabuurs M & Thijssen JHH 1985 Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Research 45 2900-2904.
100. Lemon HM 1959 Prednisone therapy of advanced mammary cancer. Cancer 12 93-107. (doi:10.1002/1097-0142(195901/02)12:1〈93::AID- CNCR2820120115〉3.0.CO;2-I)
101. Luft R, Olivecrona H & Sjögren B 1952 Hypophysectomy in man. Nordisk Medicin 14 351-354.
102. Lønning PE 2003 Study of suboptimum treatment response: lessons from breast cancer. Lancet Oncology 4 177-185. (doi:10.1016/S1470-2045(03)01022- 2)
103. Lønning PE 2004 Aromatase inhibitors in breast cancer. Endocrine-Related Cancer 11 179-189. (doi:10.1677/erc.0.0110179)
104. Lønning PE 2006 Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology 17 217-225. (doi:10.1093/annonc/mdj048)
105. Lønning PE & Ekse D 1995 A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology 55 409-412. (doi:10.1016/0960-0760(95)00180-8)
106. Lønning PE & Geisler J 2008 Indications and limitations of third-gene ration aromatase inhibitors. Expert Opinion on Investigational Drugs 17 723-739. (doi:10.1517/13543784.17.5.723)
107. Lønning PE & Knappskog S 2013 Mapping genetic alterations causing chemoresistance in cancer; identifying the roads by tracking the drivers. Oncogene [in press]. (doi:10.1038/onc.2013.48)
108. Lønning PE & Kvinnsland S 1988 Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 35 685-710. (doi:10.2165/00003495-198835060-00005)
109. Lønning PE, Kvinnsland S, Thorsen T & Ueland PM 1987 Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clinical Pharmacokinetics 13 393-406. (doi:10.2165/00003088-198713060-00004)
110. Lønning PE, Johannessen DC & Thorsen T 1989a Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. British Journal of Cancer 60 107-111. (doi:10.1038/bjc.1989.231)
111. Lønning PE, Jacobs S, Jones A, Haynes B, Powles T & Dowsett M 1991 The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer 63 789-793.
112. Lønning PE, Skulstad P, Sunde A & Thorsen T 1989b Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. Journal of Steroid Biochemistry 32 91-97. (doi:10.1016/0022-4731(89)90019-8)
113. Lønning PE, Dowsett M & Powles TJ 1990 Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. Journal of Steroid Biochemistry 35 355-366. (doi:10.1016/0022-4731(90)90241-J)
114. Lønning PE, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg PD, Mickiewicz E, Celio L, Pitt P, Mita M, Aaronson NK et al. 2000 Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology 18 2234-2244. (Pubitemid 30350215)
115. Lønning PE, Taylor PD, Anker G, Iddon J, Wie L, Jørgensen LM, Mella O & Howell A 2001 High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment 67 111-116. (doi:10.1023/A:1010619225209)
116. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J et al. 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. Journal of Clinical Oncology 23 5126-5137. (doi:10.1200/JCO.2005.07.097)
117. Lønning PE, Helle H, Duong NK, Ekse D, Aas T & Geisler J 2009 Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology 117 31-41. (doi:10.1016/j.jsbmb.2009. 06.005)
118. Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S & Dowsett M 2011 Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clinical Cancer Research 17 4948-4958. (doi:10.1158/1078-0432.CCR-11-0043)
119. MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ & Dowsett M 1992 The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer 66 692-697. (doi:10.1038/bjc.1992.339)
120. MacNeill FA, Jacobs S, Lønning PE, Powles TJ & Dowsett M 1994 Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. British Journal of Cancer 69 1171-1175. (doi:10.1038/bjc.1994.230)
121. MacNeill FA, Jacobs S, Dowsett M, Lonning PE & Powles TJ 1995 The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemotherapy and Pharmacology 36 249-254. (doi:10.1007/BF00685855)
122. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN et al. 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. Journal of Clinical Oncology 26 1965-1971. (doi:10.1200/JCO.2007.14.0228)
123. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R et al. 2003 Estrogen plus progestin and the risk of coronary heart disease. New England Journal of Medicine 349 523-534. (doi:10.1056/NEJMoa030808)
124. Masamura S, Santner SJ, Heitjan DF & Santen RJ 1995 Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. Journal of Clinical Endocrinology and Metabolism 80 2918-2925. (doi:10.1210/jc.80.10.2918)
125. Meldrum DR, Davidson BJ, Tataryn IV & Judd HL 1981 Changes in circulating steroids with aging in postmenopausal women. Obstetrics and Gynecology 57 624-627.
126. Mendelson CR, Jiang B, Shelton JM, Richardson JA & Hinshelwood MM 2005 Transcriptional regulation of aromatase in placenta and ovary. Journal of Steroid Biochemistry and Molecular Biology 95 25-33. (doi:10.1016/j.jsbmb.2005. 04.016)
127. Mieog JSD, Morden JP, Bliss JM, Coombes RC, van de Velde CJH & Comm IESS 2012 Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncology 13 420-432. (doi:10.1016/S1470-2045(11)70328-X)
128. Miller WR, Telford J, Love C, Leonard RCF, Hillier S, Gundacker H, Smith H & Dixon JM 1998 Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast 7 273-276. (doi:10.1016/S0960-9776(98)90095-9)
129. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB & Dixon JM 2009 Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. Journal of Clinical Oncology 27 1382-1387. (doi:10.1200/JCO.2008.16.8849)
130. Miller TW, Balko JM & Arteaga CL 2011 Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. Journal of Clinical Oncology 29 4452-4461. (doi:10.1200/JCO.2010.34.4879)
131. Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P et al. 2007 Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Research and Treatment 104 87-91. (doi:10.1007/s10549-006-9394-6)
132. Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens MR et al. 2008 Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. Journal of Clinical Oncology 26 3147-3152. (doi:10.1200/JCO.2007.15.4005)
133. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC et al. 2002 Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes & Control 13 741-751. (doi:10.1023/A:1020239211145)
134. Morishima A, Grumbach MM, Simpson ER, Fisher C & Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. Journal of Clinical Endocrinology and Metabolism 80 3689-3698. (doi:10.1210/jc.80.12.3689)
135. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N et al. 2010 Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116 4256-4265. (doi:10.1002/cncr.25219)
136. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F et al. 2001 Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 19 2596-2606. (Pubitemid 32451796)
137. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F et al. 2003 Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 21 2101-2109. (doi:10.1200/JCO.2003.04.194)
138. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine 361 766-776. (doi:10.1056/NEJMoa0810818)
139. Niraula S, Ocana A, Ennis M & Goodwin PJ 2012 Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Research and Treatment 134 769-781. (doi:10.1007/s10549-012-2073-x)
140. Nishihori T, Choi J, DiGiovanna MP, Thomson JG, Kohler PC, McGurn J & Chung GG 2008 Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer. Clinical Breast Cancer 8 362-365. (doi:10.3816/CBC.2008.n.043)
141. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I et al. 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Journal of Clinical Oncology 20 3386-3395. (doi:10.1200/JCO.2002.10.058)
142. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E & Asnis-Alibozek A 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. Journal of Clinical Oncology 26 556-562. (doi:10.1200/JCO.2007.11.5451)
143. Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M et al. 2009 Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 27 2809-2815. (doi:10.1200/JCO.2008. 18.2808)
144. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE et al. 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCICCTG MA.17. Journal of Clinical Oncology 24 3629-3635. (doi:10.1200/JCO.2005.05.4882)
145. Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P et al. 2011 Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. Journal of Clinical Oncology 29 2653-2659. (doi:10.1200/JCO.2010.33.2585)
146. Poortman J, Thijssen JHH & Waard FD 1981 Plasma oestrone, oestradiol and androstenedione levels in post-menopausal women: relation to body weight and height. Maturitas 3 65-71. (doi:10.1016/0378-5122(81)90021-9)
147. Powles TJ, Hickish T, Kanis JA, Tidy A & Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology 14 78-84. (Pubitemid 26022463)
148. Protani M, Coory M & Martin JH 2010 Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Research and Treatment 123 627-635. (doi:10.1007/s10549-010-0990-0)
149. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M et al. 2008 Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrineresponsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncology 9 23-28. (doi:10.1016/S1470-2045(07)70386-8)
150. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A et al. 2011 Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncology 12 1101-1108. (doi:10.1016/S1470-2045(11)70270-4)
151. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A & Ellis MJ 2012 Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Research and Treatment 136 503-511. (doi:10.1007/s10549-012-2192-4)
152. Rochira V & Carani C 2009 Aromatase deficiency in men: a clinical perspective. Nature Reviews. Endocrinology 5 559-568. (doi:10.1038/nrendo.2009. 176)
153. Sabnis G & Brodie A 2011 Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Molecular and Cellular Endocrinology 340 142-147. (doi:10.1016/j.mce.2010.09. 005)
154. Samojlik E, Veldhuis JD, Wells SA & Santen RJ 1980 Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment ofmetastatic breast carcinoma. Journal of Clinical Investigation 65 602-612. (doi:10.1172/JCI109705)
155. Santen RJ 1981 Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Research 1 183-202. (doi:10.1007/BF01806259)
156. Santen RJ, Lipton A & Kendall J 1974 Successful medical adrenalectomy with aminoglutethimide. Journal of the American Medical Association 230 1661-1665. (doi:10.1001/jama.1974.03240120029015)
157. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E & Ruby E 1978 Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. Journal of Clinical Endocrinology and Metabolism 47 1257-1265. (doi:10.1210/jcem-47-6-1257)
158. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C et al. 1981 A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. New England Journal of Medicine 305 545-551. (doi:10.1056/NEJM198109033051003)
159. Santen RJ, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura A, Lawrence J, Jr, Berstein L & Yue W 2005 Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocrine-Related Cancer 12 S61-S73. (doi:10.1677/erc.1.01018)
160. Sasano H, Anderson TJ, Silverberg SG, Santen RJ, Conway M, Edwards DP, Krause A, Bhatnagar AS, Evans DB & Miller WR 2005 The validation of new aromatase monoclonal antibodies for immunohistochemistry - a correlation with biochemical activities in 46 cases of breast cancer. Journal of Steroid Biochemistry and Molecular Biology 95 35-39. (doi:10.1016/j.jsbmb.2005.04.027)
161. Semiglazov V, Kletsel A, Semiglazov V, Zhiltzova E, Ivanov V, Dashyan G, Bozhok A, Melnikova O, Paltuev R & Berstein L 2005 Exemestane (E) versus tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ERC breast cancer (T2N1-2, T3N0-1, T4N0M0). Journal of Clinical Oncology 23 (16 Suppl) 11s (Abstr 530).
162. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S et al. 2011 PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30 2547-2557. (doi:10.1038/onc.2010. 626)
163. Sestak I, Sapunar F & Cuzick J 2009 Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. Journal of Clinical Oncology 27 4961-4965. (doi:10.1200/JCO.2009.22.0236)
164. Sestak I, Distler W, Forbes JF, Dowsett M, Howell A & Cuzick J 2010 Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. Journal of Clinical Oncology 28 3411-3415. (doi:10.1200/JCO.2009.27.2021)
165. Sluijmer AV, Heineman MA, Jong FHD & Evers JLH 1995 Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. Journal of Clinical Endocrinology and Metabolism 80 2163-2167. (doi:10.1210/jc.80.7.2163)
166. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I & Walsh G 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. Journal of Clinical Oncology 23 5108-5116. (doi:10.1200/JCO.2005.04.005)
167. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
168. Stewart HJ, Prescott RJ & Forrest APM 2001 Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. Journal of the National Cancer Institute 93 456-462. (doi:10.1093/jnci/93.6.456)
169. Tormey DC, Gray R & Falkson HC 1996 Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Journal of the National Cancer Institute 88 1828-1833. (doi:10.1093/jnci/88.24.1828)
170. Trial TW 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. Journal of the American Medical Association 273 199-208. (doi:10.1001/jama.1995.03520270033028)
171. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B et al. 2008 Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Annals of Oncology 19 1090-1096. (doi:10.1093/annonc/mdn005)
172. Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR & Vadlamudi RK 2011 Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Research and Treatment 130 377-385. (doi:10.1007/s10549-010-1312-2)
173. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET et al. 2011 Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377 321-331. (doi:10.1016/S0140-6736(10)62312-4)
174. Villarreal-Garza C, Cortes J, Andre F & Verma S 2012 mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Annals of Oncology 23 2526-2535. (doi:10.1093/annonc/mds075)
175. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D et al. 2005 The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Annals of Oncology 16 707-715. (doi:10.1093/annonc/mdi158)
176. Weigel MT, Banerjee S, Arnedos M, Salter J, A'Hern R, Dowsett M & Martin LA 2013 Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Annals of Oncology 24 126-133. (doi:10.1093/annonc/mds240)
177. Weigelt B, Warne PH & Downward J 2011 PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30 3222-3233. (doi:10.1038/onc.2011.42)
178. Wills S, Ravipati A, Venuturumilli P, Kresge C, Folkerd E, Dowsett M, Hayes DF & Decker DA 2012 Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. Journal of Oncology Practice 8 144-148. (doi:10.1200/JOP.2011.000352)
179. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P et al. 2013 Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology 31 195-202. (doi:10.1200/JCO.2011. 38.3331)
180. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69-76. (doi:10.1200/JCO.2009.24.2669)
181. Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, Moriya T, Simpson ER, Sasano H & Clyne CD 2005 Interactions between prostaglandin E-2, liver receptor homologue-1, and aromatase in breast cancer. Cancer Research 65 657-663.